About-cancer / kurapwa / kiriniki-kuyedzwa / chirwere / anal-cancer / kurapwa
Kurapa Kliniki Miedzo yeAn Cancer
Kliniki miedzo ndeyekutsvagisa zvidzidzo zvinosanganisira vanhu. Iwo emakiriniki ekuedzwa pane ino runyorwa ndeyekurapa kenza yekurapa. Yese miedzo pane irondedzero inotsigirwa neNCI.
Ruzivo rweNCI rwekutanga nezve zviedzo zvemakiriniki zvinotsanangura mhando nezvikamu zvemiyedzo uye maitirwo azvo. Kliniki miedzo inotarisa nzira nyowani dzekudzivirira, kuona, kana kubata chirwere. Iwe ungangoda kufunga nezve kutora chikamu mukutora kiriniki. Taura nachiremba wako kuti akubatsire kusarudza kana imwe yakakunakira iwe.
Miedzo 1-23 ye23
Nivolumab mushure meMubatanidzwa Modality Therapy Mukurapa Varwere vane Yakanyanya Njodzi Chikamu II-IIIB Anal Cancer
Ichi chisinganzwisisike chikamu chechipiri chemakiriniki ekuyedza anoongorora kuti zvakanaka sei nivolumab mushure mekubatana modality therapy inoshanda pakurapa varwere vane njodzi yakakura danho II-IIIB anal cancer. Immunotherapy ine monoclonal antibodies, senge nivolumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira.
Nzvimbo: 744 nzvimbo
Nivolumab ane kana asina Ipilimumab Mukurapa Varwere vane Refractory Metastatic Anal Canal Cancer
Ichi chikamu chechipiri cheyedzo yekuongorora kuti zvakanaka sei nivolumab ine kana isina ipilimumab inoshanda mukurapa varwere vane gomarara repanhengo yemazamu iyo isina kupindura kurapwa kwekutanga (refractory) uye yakapararira kune dzimwe nzvimbo mumuviri (metastatic). Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira.
Nzvimbo: 42 nzvimbo
Nivolumab neIpilimumab Mukurapa Varwere vaneHIV Yakabatana Yakadzokororwa kana Refractory Classical Hodgkin Lymphoma kana Solid Tumors Iyo Ine Metastatic kana Haigone Kubviswa neKuvhiya
Ichi chikamu I muyedzo unoongorora mhedzisiro uye yakanakisa dosi yeiyo nivolumab painopihwa neipilimumab mukurapa varwere vane hutachiona hwehutachiona hwehutachiona (HIV) inosanganisirwa yechinyakare Hodgkin lymphoma yakadzoka mushure menguva yekuvandudza kana kusapindura kurapwa, kana mamota akasimba ayo yakapararira kune dzimwe nzvimbo mumuviri kana kuti haigone kubviswa nekuvhiya. Immunotherapy ine monoclonal antibodies, senge ipilimumab uye nivolumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Ipilimumab chirwere chinorwisa mamorekuru anonzi cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 inodzora chikamu chemuviri wako nekudzivirira iyo pasi. Nivolumab rudzi rweantibody iyo yakanangana neyakagadzirirwa munhu kufa kwesero 1 (PD-1), puroteni ine chekuita nekuparadzwa kwema immune immune. Kupa ipilimumab ne nivolumab kunogona kushanda zvirinani pakurapa varwere vane hutachiwana hweHIV hwakabatana hwechinyakare Hodgkin lymphoma kana mamota akasimba achienzaniswa neipilimumab ine nivolumab chete.
Nzvimbo: 28 nzvimbo
Chidzidzo cheXmAb®20717 mune Zvidzidzo zvine Sarudzo Dzakasimba Dzakasimba Tumarara
Ichi chidimbu 1, yakawanda dosi, ichikwira dhosi yekuwedzera kudzidza kutsanangura MTD / RD uye regimen yeXmAb20717, kurondedzera kuchengetedzeka uye kushivirira, kuongorora PK uye immunogenicity, uye kutanga kuongorora anti-bundu chiitiko cheXmAb20717 mune zvidzidzo zvakasarudzwa Mberi yakasimba mamota.
Nzvimbo: 15 nzvimbo
An Investigational Immuno-therapy Kudzidza Kuongorora Kudzivirirwa uye Kubudirira kweNivolumab, uye Nivolumab Combination Therapy muVirusi-inosangana neTumors.
Chinangwa chechidzidzo ichi kuongorora kuchengetedzeka uye kushanda kwe nivolumab, uye nivolumab mubatanidzwa kurapwa, kurapa varwere vane hutachiona-hunosangana nemota. Humwe hutachiona hwave kuzivikanwa kuti hunoita basa mukuumbwa kwechimiro uye kukura. Chidzidzo ichi chichaongorora mhedzisiro yemishonga yekudzidza, muvarwere vane mhando dzinotevera dzemamota: - Anal canal cancer - Haisisiri kunyora rudzi urwu rwechirwere - Cancer cancer - Epstein Barr Virus (EBV) yakanaka gastric cancer - Haisisiri kunyora izvi mhando yemota - Merkel Cell Cancer - Kenza yepenile-Haisisiri kunyora rudzi urwu rwegomarara - Vaginal uye gomarara revhu-Haisisiri kunyora rudzi urwu rwebundu - Nasopharyngeal Cancer - Haisisiri kunyoresa rudzi urwu rwemota - Musoro uye Neck Cancer - Haisisiri kunyorera rudzi urwu bundu
Nzvimbo: 10 nzvimbo
Kudzidza kwePembrolizumab (MK-3475) muVatori vechikamu vane Advanced Solid Tumors (MK-3475-158 / KEYNOTE-158)
Muchidzidzo ichi, vatori vechikamu vane akawanda marudzi epamberi (asingachinjike uye / kana metastatic) mamota akaomarara akaenderera padanho rekurapwa kwekurapwa acharapwa nepembrolizumab.
Nzvimbo: 8 nzvimbo
Yakakwira-Dosi-Rate Brachytherapy uye Chemotherapy Mukurapa Varwere vane Nharaunda Inodzokororwa kana Residual Rectal kana Anal Cancer Inopinda Isiri-inoshanda Management.
Ichi chikamu I muyedzo unoongorora mhedzisiro uye yakanakisa dosi yeiyo yepamusoro-yedosi-chiyero brachytherapy painopihwa pamwechete nekemotherapy pakurapa varwere vane rectal kana anal gomarara iro rakadzoka kana rakatowedzera uye risingakwanise kurapwa nekuvhiyiwa. Brachytherapy, inozivikanwawo senge radiation radiation, inoshandisa radioactive zvinhu zvakaiswa mukati kana padyo nebundu kuuraya tumarara maseru. High-dose-rate (HDR) brachytherapy inoshandisa iyo radioactive zvinhu kuendesa yakakwira radiation mwero munguva pfupi yenguva kune bundu. Inogona zvakare kutumira mashoma radiation kune ari pedyo ane hutano matishu uye inogona kudzora njodzi yemhedzisiro mhedzisiro. Zvinodhaka zvinoshandiswa mu chemotherapy, senge capecitabine uye fluorouracil, zvinoshanda munzira dzakasiyana kumisa kukura kwemarara maseru, kungave nekuuraya maseru, nekuamisa iwo kubva pakupatsanuka, kana nekuamisa iwo pakupararira.
Nzvimbo: 6 nzvimbo
Pembrolizumab Mukurapa Varwere vane Metastatic kana Yemunharaunda Yepamberi Anal Kenza Iyo Isingakwanise Kubviswa nekuvhiya.
Ichi chikamu chechipiri cheyedzo yekuongorora mashandiro anoita pembrolizumab pakurapa varwere vane gomarara repamusana rakapararira kune dzimwe nzvimbo mumuviri kana iro rakapararira kubva panzvimbo yayo yekutanga yekukura kusvika kumatumbu ari pedyo kana ma lymph node uye risingakwanise kubviswa nekuvhiyiwa. Immunotherapy ine monoclonal antibodies, senge pembrolizumab, inogona kubatsira immune immune kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira.
Nzvimbo: 5 nzvimbo
Kuvhiya Mukurapa Varwere vane Ekutanga Stage Anal Canal kana Perianal Cancer uye HIV Yakanaka
Ichi chikamu chechipiri cheyedzo yekuongorora kuvhiya mukurapa varwere vane canal anal kana perianal kenza idiki uye isina kupararira zvakadzika mumatumbu uye hutachiona hwehutachiona hwehutachiona hweHIV. Kuvhiya kwemuno kunogona kuve kurapwa kwakachengeteka pamwe nemimwe mhedzisiro pane kuvhiya kukuru kana radiation uye chemotherapy.
Nzvimbo: 5 nzvimbo
Chiyero chekutsvaga nekutsvaga Yakachengeteka Dosi yechinhu Chitsva (BI 754091) yevarwere vane Solid Tumors.
Chinangwa chikuru chedosi-yekukwira chikamu chekuyedza ndechekuona kuchengetedzeka uye kushivirira, uye kuona iyo Maximum Tolerated Dose uye / kana Yakakurudzirwa Phase 2 Dose (RP2D) yeBI 754091 pahwaro hwevarwere vane dosi-inomisikidza toxicities (DLTs) mune varwere vane vakasarudzwa vepamberi solid malignancies. Kuchengeteka uye kushivirira zvichaongororwa nekutarisa kuitika kwezviitiko zvakashata (AEs), zvakakomba AEs (SAE), uye marabhoramu paramende zvisizvo, pamwe neshanduko kuzviratidzo zvakakosha. Zvimwe zvinangwa zvechipiri kutsunga kweiyo PK chimiro cheBI 754091 mushure meimwe uye yakawanda mitezo yeBI 754091, uye yekutanga ongororo yeantitumour chiitiko. Muchikamu chekuwedzera-chiyero chemuyedzo, zvinangwa zvikuru ndezvekuenderera mberi nekuongorora kuchengetedzeka, kushanda, chimiro chePK,
Nzvimbo: 3 nzvimbo
Stereotactic Radiosurgery Mukurapa Varwere vane Oligometastatic Chirwere
Ichi chikamu chechipiri cheyedzo inoongorora mashandiro anoita stereotactic radiosurgery pakurapa varwere vane gomarara rakapararira kusvika kunzvimbo shanu kana shoma mumuviri uye inosanganisira 3 kana mashoma nhengo (oligometastatic chirwere). Stereotactic radiosurgery, inozivikanwawo seye stereotactic muviri radiation radiation, ndiyo yakasarudzika radiation kurapwa iyo inounza imwechete, yakakwira dosi yemwaranzi yakananga kune iro bundu uye inogona kuuraya akawanda mamota maseru uye inokonzeresa zvishoma kukuvara kune zvakajairika nyama.
Nzvimbo: 3 nzvimbo
Chidzidzo cheINCMGA00012 muSquamous Carcinoma yeAnal Canal Inotevera Platinum-Yakavakirwa Chemotherapy (POD1UM-202)
Chinangwa chechidzidzo ichi ndechekuongorora kushanda kweINCMGA00012 mune vatori vechikamu vane nzvimbo yepamusoro kana metastatic squamous carcinoma yeanal canal (SCAC) avo vakafambira mberi mushure meplatinum-based chemotherapy.
Nzvimbo: 4 nzvimbo
Artesunate Mukurapa Varwere vane Yakakwira-Giredhi Anal Intraepithelial Neoplasia
Ichi chikamu ini muedzo unoongorora mhedzisiro uye yakanyanya dhosi yeartesunate pakurapa varwere vane yakakwira-giredhi anal intraepithelial neoplasia. Anal intraepithelial neoplasia ndiwo maseru anononoka anogona kana kusave kenza mune ramangwana. Dzakawanda dzeshanduko dzinotungamira kugomarara dzinokonzerwa nepapillomavirus yevanhu (HPV). Artesunate inogona kuuraya masero ane hutachiona hweHPV.
Nzvimbo: 2 nzvimbo
Chidzidzo cheLY3434172, PD-1 uye PD-L1 Bispecific Antibody, muAdvanced Cancer
Chinangwa chikuru cheichi chidzidzo ndechekuongorora kuchengetedzeka uye kusashivirira kwechirwere chekudzidza LY3434172, PD-1 / PD-L1 bispecific antibody, muvatori vechikamu vane mamota akasimba akakwira.
Nzvimbo: MD Anderson Cancer Center, Houston, Texas
SL-279252 (PD1-Fc-OX40L) mune Zvidzidzo zvine Zvipenga Zvakasimba Zvakasimba kana maLymphomas
Ichi chikamu che1 chekutanga muvanhu, yakavhurika chitambi, mizhinji-yepakati, kuwedzera kwedosi uye kuongorora kuwedzerwa kwedosi kuongorora kuchengetedzwa, kushivirira, PK, anti-bundu chiitiko uye pharmacodynamic mhedzisiro yeSL-279252 mune zvidzidzo zvine mamota akasimba akasimba kana lymphomas. .
Nzvimbo: MD Anderson Cancer Center, Houston, Texas
LET-IMPT uye Yakajairwa Chemotherapy Mukurapa Varwere neNewly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer
Ichi chikamu chechipiri cheyedzo chinoongorora mhedzisiro yeLET-IMPT uye yakajairwa chemotherapy, uye nemabatiro avanoita mukurapa varwere vachangobva kuongororwa danho I-III anal canal squamous cell cancer. LET-IMPT imhando yekurapwa nemwaranzi inoshandisa simba rakawanda proton "mabhamuti" ku "penda" muyero we radiation muchinangwa uye zvinogona kubatsira kuuraya maseru emota uye kudzikisa tumota. Kupa LET-IMPT uye yakajairwa chemotherapy inogona kushanda zvirinani pakurapa varwere vane anal canal squamous cell cancer.
Nzvimbo: MD Anderson Cancer Center, Houston, Texas
VGX-3100 uye Electroporation Mukurapa Varwere vane HIV-Positive Yakakwira-Giredhi Anal Lesions
Ichi chikamu II miedzo inoongorora mashandiro anoita munhu papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids yekurapa jekiseni VGX-3100 (VGX-3100) uye basa rekugadzira magetsi pakurapa varwere vane hutachiona hwehutachiona hwehutachiona hweHIV (HIV) -zvakanaka zvepamusoro-giredhi anal lesion. Majekiseni akagadzirwa kubva kuDNA anogona kubatsira muviri kuvaka mhinduro inoshanda yekuzvidzivirira kumatumbu kuuraya maseru emota. Electroporation inobatsira pores mumasero emuviri wako kutora mushonga kuti usimbise mhinduro yemasoja emuviri wako. Kupa VGX-3100 uye kusanganisa magetsi pamwechete zvinogona kushanda zvirinani pakurapa varwere vane maronda epamusoro-grey anal.
Nzvimbo: 2 nzvimbo
DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Therapeutic Vaccine INO-3112 uye Durvalumab Mukurapa Varwere vane Dzokororo kana Metastatic Human Papillomavirus Associated Cancers
Ichi chikamu chechipiri cheyedzo yekuongorora kuti zvakanaka sei deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids yekurapa mushonga INO-3112 uye durvalumab inoshanda pakurapa varwere vane vanhu papillomavirus kanzura dzakadzoka kana kupararira kune vamwe nzvimbo mumuviri. Mishonga yekudzivirira inogadzirwa nehutachiona hweshanduko inogona kubatsira muviri kuvaka immune system yekuuraya maseru emota. Immunotherapy ine monoclonal antibodies, senge durvalumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Kupa DNA plasmid-encoding interleukin-12 / HPV DNA plasmids yekurapa mushonga INO-3112 uye durvalumab inogona kushanda zvirinani pakurapa varwere vane vanhu papillomavirus kanzura.
Nzvimbo: MD Anderson Cancer Center, Houston, Texas
M7824 mune Zvidzidzo zvine HPV Yakabatana Malignancies
Background: MuUnited States, gore rega rega kune anopfuura makumi matatu ezviitiko zvevanhu papillomavirus (HPV) inosangana nekenza. Mimwe yekenza iyi inowanzo kurapwa uye haina kuvandudzwa nemushonga wakajairika. Vatsvagiri vanoda kuona kana mushonga mutsva M7824, unonanga nekuvhara nzira inodzivirira immune system kubva pakurwisa kenza inogona kudzora mamota kune vanhu vane mamwe maCancer eHPV. Zvinangwa: Kuona kana mushonga M7824 uchikonzera mamota kudzikira. Kukodzera: Vakuru vane makore gumi nemasere zvichikwira vane kenza inosanganisirwa neHIVV hutachiona. Dhizaini: Vatori vechikamu vanozoongororwa neyakaitika nhoroondo yezvokurapa uye bvunzo dzepanyama. Vanozoongorora zviratidzo zvavo uye maitiro avanoita zviito zvakajairika. Vachave nemasikirini emuviri. Vachapa ropa uye weti sampuli. Vachave nemuenzaniso wetumhu yavo yeturu yakatorwa kana imwe isipo. Vatori vechikamu vanozove nemagetsi ekuongorora moyo wavo. Ipapo vanozowana chinodhaka chekudzidza kuburikidza netubhu mutete mutsinga yeruoko. Vatori vechikamu vanozowana mushonga uyu masvondo maviri ega ega makumi maviri nematanhatu (gore rimwe chete). Iyi ndiyo 1 kosi. Mushure mekosi, vatori vechikamu vanozotariswa asi havazotora mushonga wekudzidza. Kana mamiriro avo akawedzera, vachatanga imwe kosi nemushonga. Maitiro aya anogona kudzokororwa kakawanda sekudikanwa. Kurapa kunomira kana iye anenge atora chikamu aine mhedzisiro yakaipa kana mushonga unomira kushanda. Munguva yese yechidzidzo, vatori vechikamu vachadzokorora zvimwe kana zvese zvekuyedza kuongorora. Mushure mekunge vatori vechikamu varega kutora chinwiwa ichi, vanozove nekutevera-kwekushanya uye kudzokorora kumwe kuongorora kwekuyedza. Vachawana nguva nenguva yekutevera mafoni. ... Ipapo vanozowana chinodhaka chekudzidza kuburikidza netubhu mutete mutsinga yeruoko. Vatori vechikamu vanozowana mushonga uyu masvondo maviri ega ega makumi maviri nematanhatu (gore rimwe chete). Iyi ndiyo 1 kosi. Mushure mekosi, vatori vechikamu vanozotariswa asi havazotora mushonga wekudzidza. Kana mamiriro avo akawedzera, vachatanga imwe kosi nemushonga. Maitiro aya anogona kudzokororwa kakawanda sekudikanwa. Kurapa kunomira kana iye anenge atora chikamu aine mhedzisiro yakaipa kana mushonga unomira kushanda. Munguva yese yechidzidzo, vatori vechikamu vachadzokorora zvimwe kana zvese zvekuyedza kuongorora. Mushure mekunge vatori vechikamu varega kutora chinwiwa ichi, vanozove nekutevera-kwekushanya uye kudzokorora kumwe kuongorora kwekuyedza. Vachawana nguva nenguva yekutevera mafoni. ... Ipapo vanozowana chinodhaka chekudzidza kuburikidza netubhu mutete mutsinga yeruoko. Vatori vechikamu vanozowana mushonga uyu masvondo maviri ega ega makumi maviri nematanhatu (gore rimwe chete). Iyi ndiyo 1 kosi. Mushure mekosi, vatori vechikamu vanozotariswa asi havazotora mushonga wekudzidza. Kana mamiriro avo akawedzera, vachatanga imwe kosi nemushonga. Maitiro aya anogona kudzokororwa kakawanda sekudikanwa. Kurapa kunomira kana iye anenge atora chikamu aine mhedzisiro yakaipa kana mushonga unomira kushanda. Munguva yese yechidzidzo, vatori vechikamu vachadzokorora zvimwe kana zvese zvekuyedza kuongorora. Mushure mekunge vatori vechikamu varega kutora chinwiwa ichi, vanozove nekutevera-kwekushanya uye kudzokorora kumwe kuongorora kwekuyedza. Vachawana nguva nenguva yekutevera mafoni. ... vatori vechikamu vanozotariswa asi havazotora mushonga wekudzidza. Kana mamiriro avo akawedzera, vachatanga imwe kosi nemushonga. Maitiro aya anogona kudzokororwa kakawanda sekudikanwa. Kurapa kunomira kana iye anenge atora chikamu aine mhedzisiro yakaipa kana mushonga unomira kushanda. Munguva yese yechidzidzo, vatori vechikamu vachadzokorora zvimwe kana zvese zvekuyedza kuongorora. Mushure mekunge vatori vechikamu varega kutora chinwiwa ichi, vanozove nekutevera-kwekushanya uye kudzokorora kumwe kuongorora kwekuyedza. Vachawana nguva nenguva yekutevera mafoni. ... vatori vechikamu vanozotariswa asi havazotora mushonga wekudzidza. Kana mamiriro avo akawedzera, vachatanga imwe kosi nemushonga. Maitiro aya anogona kudzokororwa kakawanda sekudikanwa. Kurapa kunomira kana iye anenge atora chikamu aine mhedzisiro yakaipa kana mushonga unomira kushanda. Munguva yese yechidzidzo, vatori vechikamu vachadzokorora zvimwe kana zvese zvekuyedza kuongorora. Mushure mekunge vatori vechikamu varega kutora chinwiwa ichi, vanozove nekutevera-kwekushanya uye kudzokorora kumwe kuongorora kwekuyedza. Vachawana nguva nenguva yekutevera mafoni. ... Mushure mekunge vatori vechikamu varega kutora chinwiwa ichi, vanozove nekutevera-kwekushanya uye kudzokorora kumwe kuongorora kwekuyedza. Vachawana nguva nenguva yekutevera mafoni. ... Mushure mekunge vatori vechikamu varega kutora chinwiwa ichi, vanozove nekutevera-kwekushanya uye kudzokorora kumwe kuongorora kwekuyedza Vachawana nguva nenguva yekutevera mafoni. ...
Nzvimbo: National Institutes of Health Clinical Center, Bethesda, Maryland
MnSOD Mimetic BMX-001 Mukurapa Varwere vane Anal Cancer Vanoitwa Radiation Therapy uye Chemotherapy
Ichi chikamu I chekuyedza chinoongorora yakanyanya dhosi ye MnSOD mimetic BMX-001 yekudzora mhedzisiro kune varwere vane kenza yekumashure vari kurapwa radiation uye chemotherapy. Chemoprotective mishonga, yakadai seBMX-001, inogona kuchengetedza maseru akajairwa kubva kumhedzisiro yemakemotherapy apo ichiwedzera kuuraya kwemarara.
Nzvimbo: Yunivhesiti yeNebraska Medical Center, Omaha, Nebraska
Atezolizumab uye Bevacizumab Mukurapa Varwere vane Rare Solid Tumors
Ichi chikamu chechipiri cheyedzo yekuongorora mashandisiro atezolizumab uye bevacizumab anoshanda pakurapa varwere vane zvisingawanzo yakasimba mamota. Immunotherapy ine monoclonal antibodies, senge atezolizumab uye bevacizumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwemasero emarara kukura nekupararira.
Nzvimbo: MD Anderson Cancer Center, Houston, Texas
Vaccine Therapy uye Cyclophosphamide Mukurapa Varwere vane HLA-A * 02 Yakanaka Yakadzoreredzwa, Refractory, kana Metastatic HPV16-Inoenderana Oropharyngeal, Cervical, kana Anal Cancer
Iyi chikamu Ib / II yekuyedza inoongorora mhedzisiro uye yakanyanya dhizaini yeHIVV16-E711-19 nanomer jekiseni DPX-E7 uye kuona kuti inoshanda sei painopihwa pamwechete necyclophosphamide mukurapa varwere vane HLA-A * 02 yakanaka, papillomavirus yevanhu 16 ( HPV16) -yakabatana oropharyngeal, yemuromo wechibereko, kana yekanzuru gomarara rakadzoka, haripindure kurapwa, kana rapararira kune dzimwe nhengo dzomuviri. Mishonga yekudzivirira inogadzirwa nehutachiona hweshanduko inogona kubatsira muviri kuvaka immune system yekuuraya maseru emota. Zvinodhaka zvinoshandiswa mukemotherapy, senge cyclophosphamide, zvinoshanda munzira dzakasiyana kumisa kukura kwemarara maseru, kungave nekuuraya maseru, nekuamisa kuti asaparadzane, kana nekuamisa iwo pakupararira. Kupa HPV16-E711-19 nanomer jekiseni DPX-E7 pamwe necyclophosphamide inogona kushanda zvirinani pakurapa varwere vane HPV16-inoenderana oropharyngeal,
Nzvimbo: Dana-Farber Cancer Institute, Boston, Massachusetts
Nivolumab uye Ipilimumab Mukurapa Varwere vane Rare Tumors
Ichi chikamu II chidzidzo chekuyedza nivolumab uye ipilimumab mukurapa varwere vane tumarara tusingawanzo. Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Uyu muedzo unonyora vatori vechikamu kune anotevera macohort anoenderana nemamiriro ezvinhu: 1. Epithelial tumors yemhino mhango, sinuses, nasopharynx: A) squamous cell carcinoma ine akasiyana emhino mhango, sinuses, uye nasopharynx uye trachea (kusanganisa laryngeal, nasopharyngeal cancer [NPC] , uye squamous cell carcinoma yemusoro nemutsipa [SCCHN]) B) Adenocarcinoma uye akasiyana emumhino, matadza, uye nasopharynx (yakavharwa kusvika pakuwedzera 07/27/2018) 2. Epithelial tumors yematota makuru emate (akavharwa kusvika mukuwedzera 03 / 20/2018) 3. Salivary gland mhando tumota dzemusoro nemutsipa, muromo, esophagus, dumbu, trachea nemapapu, zamu uye imwe nzvimbo (yakavharwa kusvika pakuwedzera) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. squamous cell carcinoma ine akasiyana eGI turakiti (mudumbu mudumbu ura, colon, rectum, pancreas) (yakavharwa kusvika mukuwedzera 10/17/2018) 7. Fibromixoma uye yakadzika giredhi mucinous adenocarcinoma (pseudomixoma peritonei) ye appendikisi uye ovary (yakavharwa kusvika pakuwedzera 03/20/2018) 8. Kazhinji maronda epancreatic anosanganisira acinar cell carcinoma, mucinous cystadenocarcinoma kana serous cystadenocarcinoma. Pancreatic adenocarcinoma haina kukodzera 9. Intrahepatic cholangiocarcinoma (yakavharwa kusvika mukuwedzera 03/20/2018) 10. Extrahepatic cholangiocarcinoma uye bile duct tumors (yakavharwa kusvika mukuwedzera 03/20/2018) 11. Sarcomatoid carcinoma yemapapu 12. Bronchoalveolar carcinoma lung. Mamiriro ezvinhu aya ave kunzi adenocarcinoma in situ, adenocarcinoma inovhiringidza, lepidic yakanyanya adenocarcinoma, kana inopinza mucinous adenocarcinoma 13. Zvisiri-epithelial tumors yeovary: A) Germ cell cell tumor of ovary B) Mullerian yakavhenganiswa bundu uye adenosarcoma (yakavharwa Kuwedzera 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (yakavharwa kusvika pakuwedzera 04/15/2019) 15. Transitional cell carcinoma kunze kweiyo renal, chiuno, ureter, kana dundira (yakavharwa kusvika pakuwedzera 04 / 15/2019) 16. Sermarara bundu rema testes uye extragonadal germ tumors: Apocrine tumors / extramammary Paget's disease 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Clear cell cancer cancer. 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (yakaipa inosanganiswa mamota eMullerian) (yakavharwa kusvika pakuwedzera) 45. Bvisa cell cell cancer endometrial 46. Bvisa sero. gomarara rezvipenga 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] inofanira kunyoreswa muCohort 22; prostatic neuroendocrine carcinomas inofanirwa kunyoreswa muCohort 53). Diki kenza yemapapu kenza haina kukodzera 53. Kurapa-kunobuda kudiki-sero neuroendocrine kenza yeprostate (t-SCNC) Bvisa sero gomarara remuromo wechibereko 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (yakaipa yakasanganiswa mamota eMullerian) (yakavharwa kusvika pakuwedzera) 45. Bvisa kenza yemukondombera endometrial 46. Bvisa kenza yesero ovarian 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Mudiki. cell carcinoma yeiyo ovary, hypercalcemic mhando 50. PD-L1 yakawedzera mamota 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] inofanirwa kunyoreswa muCohort 22; prostatic neuroendocrine carcinomas inofanirwa kunyoreswa muCohort 53). Kenza diki yemapapu yemapapu haina kukodzera 53. Mushonga-unobuda mudiki-sero neuroendocrine kenza yeprostate (t-SCNC) Bvisa sero gomarara remuromo wechibereko 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (yakaipa yakasanganiswa mamota eMullerian) (yakavharwa kusvika pakuwedzera) 45. Bvisa kenza yemukondombera endometrial 46. Bvisa kenza yesero ovarian 47. cell carcinoma yeiyo ovary, hypercalcemic mhando 50. PD-L1 yakawedzera mamota 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] inofanirwa kunyoreswa muCohort 22; prostatic neuroendocrine carcinomas inofanirwa kunyoreswa muCohort 53). Kenza diki yemapapu yemapapu haina kukodzera 53. Mushonga-unobuda mudiki-sero neuroendocrine kenza yeprostate (t-SCNC) Bvisa kenza yesero ovarian 47. Gestational trophoblastic chirwere (GTD) 48. Gallbladder cancer 49. Diki cell carcinoma yeiyo ovary, hypercalcemic mhando 50. PD-L1 yakawedzera mamota 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine bundu [PNET ] inofanirwa kunyoreswa muCohort 22; prostatic neuroendocrine carcinomas inofanirwa kunyoreswa muCohort 53). Kenza diki yemapapu yemapapu haina kukodzera 53. Mushonga-unobuda mudiki-sero neuroendocrine kenza yeprostate (t-SCNC) Bvisa kenza yesero ovarian 47. Gestational trophoblastic chirwere (GTD) 48. Gallbladder cancer 49. Diki cell carcinoma yeiyo ovary, hypercalcemic mhando 50. PD-L1 yakawedzera mamota 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine bundu [PNET ] inofanirwa kunyoreswa muCohort 22; prostatic neuroendocrine carcinomas inofanirwa kunyoreswa muCohort 53). Kenza diki yemapapu yemapapu haina kukodzera 53. Mushonga-unobuda mudiki-sero neuroendocrine kenza yeprostate (t-SCNC) Prostatic neuroendocrine carcinomas inofanira kunyoreswa muCohort 53). Kenza diki yemapapu yemapapu haina kukodzera 53. Mushonga-unobuda mudiki-sero neuroendocrine kenza yeprostate (t-SCNC) Prostatic neuroendocrine carcinomas inofanira kunyoreswa muCohort 53). Kenza diki yemapapu yemapapu haina kukodzera 53. Mushonga-unobuda mudiki-sero neuroendocrine kenza yeprostate (t-SCNC)
Nzvimbo: 878 nzvimbo
